Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $574.86, for a total value of $5,461,170.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $23,289,303.18. This trade represents a 19.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

United Therapeutics Stock Down 0.2%

UTHR stock opened at $577.58 on Thursday. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $607.89. The firm has a market cap of $25.32 billion, a PE ratio of 20.70, a price-to-earnings-growth ratio of 1.65 and a beta of 0.75. The business has a 50 day moving average of $522.64 and a 200 day moving average of $487.71.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter last year, the company earned $6.19 EPS. On average, research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Oppenheimer lifted their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Bank of America lifted their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Raymond James Financial assumed coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Finally, Royal Bank Of Canada lifted their target price on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Ten investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $601.50.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Nations Financial Group Inc. IA ADV boosted its stake in shares of United Therapeutics by 1.8% in the 1st quarter. Nations Financial Group Inc. IA ADV now owns 4,116 shares of the biotechnology company’s stock worth $2,441,000 after buying an additional 72 shares during the last quarter. Rockefeller Capital Management L.P. boosted its stake in shares of United Therapeutics by 10.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,323 shares of the biotechnology company’s stock worth $645,000 after buying an additional 127 shares during the last quarter. Corient Private Wealth LLC boosted its stake in shares of United Therapeutics by 13.5% in the 4th quarter. Corient Private Wealth LLC now owns 19,248 shares of the biotechnology company’s stock worth $9,379,000 after buying an additional 2,289 shares during the last quarter. Rehmann Capital Advisory Group boosted its stake in shares of United Therapeutics by 9.8% in the 4th quarter. Rehmann Capital Advisory Group now owns 3,619 shares of the biotechnology company’s stock worth $1,767,000 after buying an additional 324 shares during the last quarter. Finally, Tobam boosted its stake in shares of United Therapeutics by 28.9% in the 4th quarter. Tobam now owns 9,857 shares of the biotechnology company’s stock worth $4,803,000 after buying an additional 2,211 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.